Dr. Mayur Subhash Narkhede, MD

Dr. Narkhede practices at Javon Bea Hospital in Rockford, Illinois.

Dr. Narkhede's NPI, 1730529777, was assigned on July 3, 2013. Dr. Narkhede holds Alabama license 37990.

Dr. Narkhede's primary practice is Javon Bea Hospital, at 8201 E Riverside Blvd, Rockford, IL 61114 in Winnebago County. The practice phone is (815) 971-5000.

Dr. Narkhede's primary practice is Javon Bea Hospital in Rockford, Illinois. Dr. Narkhede is also affiliated with Javon Bea Hospital-Riverside. The medical group on file is Mercyhealth Physicians. Dmand AI also links Dr. Narkhede to 1 more hospital and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Narkhede practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Narkhede's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Narkhede is licensed in Alabama.

CMS data shows 621 Medicare services from Dr. Narkhede across 5 procedure codes in 2024, for 159 Medicare patients. Medicare paid $29,956 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 159 Medicare patients who saw Dr. Narkhede in 2024. The largest group is 65 to 74, with 68 patients. 75% of them have high blood pressure, and 74% have high cholesterol. Their average risk score is 1.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Narkhede's median patient age at 70, with 53% women.

In 2024, Dr. Narkhede wrote 637 Medicare Part D claims for 103 patients. 62% of them were for generic drugs. CMS names the drug for 508 of them, across 16 drugs with 11 or more claims each, at $2,795,431 in total drug cost. In 2023, CMS named 423 claims across 14 drugs.

Dr. Narkhede accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Narkhede as offering telehealth.

Dmand AI links 25 papers to Dr. Narkhede, published from 2016 to 2025. 2023 was the busiest year, with 4. The most frequent topics are Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols and Doxorubicin. Dr. Narkhede has published most often in Clin Lymphoma Myeloma Leuk. Dr. Narkhede's most frequent co-authors are Amitkumar N. Mehta, MD, Gaurav Goyal and Bruce David Cheson, MD.

Dmand AI links Dr. Narkhede to 5 clinical trials, 3 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, B-Cell and Lymphoma, Large B-Cell, Diffuse. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 198 general payments to Dr. Narkhede from 23 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 59% of the total. Genentech, Inc. paid the most, $43,539. It also lists 13 research payments totaling $89,251 from 2023 to 2025.